Michael S Lee, Baek-Yeol Ryoo, Chih-Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P Hack, Jessica Spahn, Bo Liu, Heba Abdullah, Yulei Wang, Aiwu Ruth He, Kyung-Hun Lee
BACKGROUND: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through multiple mechanisms and augmented antitumour activity in multiple malignancies. We aimed to assess the efficacy and safety of atezolizumab (anti-PD-L1) alone and combined with bevacizumab (anti-VEGF) in patients with unresectable hepatocellular carcinoma. METHODS: GO30140 is an open-label, multicentre, multiarm, phase 1b study that enrolled patients at 26 academic centres and community oncology practices in seven countries worldwide...
June 2020: Lancet Oncology